<DOC>
	<DOCNO>NCT01844518</DOCNO>
	<brief_summary>The purpose study estimate Abatacept steady-state trough concentration ( Cmin ) Day 113 child adolescent pJIA</brief_summary>
	<brief_title>Pharmacokinetics , Efficacy Safety Abatacept Administered Subcutaneously ( SC ) Children Adolescents With Active Polyarticular Juvenile Idiopathic Arthritis ( pJIA ) Inadequate Response ( IR ) Biologic Non Biologic Disease Modifying Anti-rheumatic Drugs ( DMARDs )</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Juvenile</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<criteria>JIA subject ( male female ) , age 217 year active disease insufficient therapeutic response intolerance least one non biologic DMARD Tumor Necrosis Factor ( TNFα ) antagonists least 3 month prior screen Subjects TNFα inadequate response ( prior biologic ) restrict 30 % population Subjects must history least 5 joint active disease must currently active articular disease ≥2 active joint ≥2 joint limitation motion . Subjects rheumatic disease major chronic inflammatory/immunologic disease , active uveitis , systemic JIA active systemic feature ( within period 6 month prior enrollment ) , persistent Oligoarthritis JIA , fail 3 TNFα antagonist biological DMARDs exclude . Active systemic disease : ( ie , extraarticular feature systemic JIA include fever , rash , organomegaly ) within period 6 month prior randomization . Subjects fail two TNFα antagonist biologic DMARDs</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>